In an inspiring display of community commitment, Fred's Team, affiliated with the renowned Memorial Sloan Kettering Cancer Center (MSK), raised over $10 million for cancer research during its 30th anniversary season in 2025. This remarkable achievement marks the highest amount ever raised by the team in a single year and underscores the vital role that community-driven efforts play in advancing cancer treatment and research.

A Legacy of Support and Innovation

Since its inception in 1995, Fred's Team has mobilized runners and donors alike to support transformative cancer research at MSK. To date, the initiative has contributed more than $130 million directly to the center, with every dollar raised going straight to researchers and clinical trials. This funding is crucial for developing innovative treatments that have the potential to save lives and improve patient outcomes. Dr. Sarat Chandarlapaty, a breast cancer specialist at MSK, reflects on the evolution of cancer care over the past three decades. "When Fred’s Team was founded, cancer care looked very different. Immunotherapy and precision oncology were just beginning to emerge," he noted. The funds raised by Fred's Team have significantly contributed to this transformation, allowing researchers to tackle some of cancer’s most pressing challenges.

Impactful Research Supported by Fred's Team

The funds raised through Fred's Team have facilitated groundbreaking advancements in cancer treatment. Notable achievements include: - Improved Pediatric Leukemia Treatments: Research funded by Fred's Team has led to the development of novel chemotherapy regimens and stem cell transplantation techniques, dramatically increasing survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) from under 10% in the 1970s to nearly 90% today. - Revolutionary Immunotherapy Trials: A clinical trial of the immunotherapy drug dostarlimab (Jemperli®) for a rare subtype of rectal cancer yielded extraordinary results, with every participant experiencing complete cancer remission without the need for surgery. Such findings could redefine treatment protocols for this cancer type. - Targeted Therapy for Gliomas: The recent FDA approval of vorasidenib (Voranigo®) for low-grade gliomas marks a significant milestone, as it represents the first new treatment option for this type of brain tumor in over two decades. This development is particularly crucial for younger patients, as gliomas are the most common brain tumors found in individuals under 50.

The Role of Community in Cancer Research Funding

The success of Fred's Team serves as a powerful reminder of the impact that community engagement can have in the fight against cancer. With over 1,200 runners participating in various events, including the TCS New York City Marathon and the United Airlines NYC Half, the collective effort of individuals united by a shared purpose has proven to be an effective fundraising strategy. Christine Burke, Chief Commercial Officer of New York Road Runners, emphasized the importance of this partnership, stating, "Surpassing $10 million raised in a single season is an incredible testament to the power of this partnership and the impact it brings to Memorial Sloan Kettering Cancer Center." This sentiment reflects a growing awareness among participants that their efforts extend beyond personal achievement; they contribute to a larger mission aimed at eradicating cancer.

AI and the Future of Cancer Research

In the rapidly evolving landscape of oncology, artificial intelligence (AI) plays a pivotal role in enhancing cancer research and treatment. The development of tools such as MSK-IMPACT®, which analyzes over 500 genes linked to cancer, exemplifies how AI can aid in diagnosing and tailoring treatments to individual patients. The integration of AI in cancer research not only accelerates the pace of discovery but also enhances the precision of therapies, aligning with the goals of initiatives like Fred's Team. As researchers continue to explore the potential of AI in oncology, the funding generated by community efforts like Fred's Team will be instrumental in supporting innovative projects that harness these technologies. Such advancements could lead to breakthroughs in understanding cancer biology, improving diagnostic accuracy, and personalizing treatment plans for patients.

Conclusion

The historic fundraising achievement by Fred's Team not only highlights the power of collective action in combating cancer but also reinforces the importance of continued investment in research and innovation. For cancer patients, their families, and advocates, this milestone brings renewed hope that, with sufficient resources, significant advancements in treatment and care are possible. As the journey to end cancer continues, staying informed about the latest developments in cancer research and the role of AI in improving patient outcomes is crucial. For more updates on this intersection of technology and oncology, visit CureCancerWithAi.com, a resource dedicated to following the progress in cancer research and treatment innovation.

Readers who want more plain-language context on AI and oncology can also explore the Cure Cancer With AI blog and learn more about the project.